

Iran (Islamic Republic of)

Tuberculosis profile

Population 2017

81 million

Estimates of TB burden*, 2017	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.85 (0.76–0.94)	1 (0.94–1.2)
Mortality (HIV+TB only)	0.031 (<0.01–0.066)	0.04 (0.01–0.08)
Incidence (includes HIV+TB)	11 (8.7–14)	14 (11–18)
Incidence (HIV+TB only)	0.3 (0.2–0.43)	0.37 (0.24–0.53)
Incidence (MDR/RR-TB)**	0.2 (0.1–0.32)	0.24 (0.13–0.39)

Estimated TB incidence by age and sex (thousands)*, 2017

	0-14 years	> 14 years	Total
Females	0.64 (0.39–0.89)	4.6 (2.8–6.4)	5.2 (3.4–7)
Males	0.66 (0.4–0.92)	5.5 (3.3–7.6)	6.1 (4–8.3)
Total	1.3 (0.93–1.7)	10 (7.2–13)	11 (8.7–14)

TB case notifications, 2017

Total cases notified	9 260
Total new and relapse	9 051
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	83%
- % pulmonary	73%
- % bacteriologically confirmed among pulmonary	73%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2017	80% (63–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2017	0.08 (0.06–0.1)

TB/HIV care in new and relapse TB patients, 2017

	Number	(%)
Patients with known HIV-status who are HIV-positive	303	4%
- on antiretroviral therapy	217	72%

Drug-resistant TB care, 2017	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			130 (84–180)
Estimated % of TB cases with MDR/RR-TB	1.3% (0.69–2.1)	8.3% (5.9–11)	
% notified tested for rifampicin resistance	35%	74%	3 778
MDR/RR-TB cases tested for resistance to second-line drugs			20
Laboratory-confirmed cases		MDR/RR-TB: 52, XDR-TB: 2	
Patients started on treatment ****		MDR/RR-TB: 46, XDR-TB: 2	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2016	86%	9 205
Previously treated cases, excluding relapse, registered in 2016	76%	200
HIV-positive TB cases registered in 2016	70%	320
MDR/RR-TB cases started on second-line treatment in 2015	63%	48
XDR-TB cases started on second-line treatment in 2015		0

TB preventive treatment, 2017

% of HIV-positive people (newly enrolled in care) on preventive treatment	10%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	> 100%

TB financing, 2018

National TB budget (US\$ millions)	5.4
Funding source: domestic, international, 100% unfunded	


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2017




■ Females ■ Males □ Incidence

Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



■ Unfunded
■ Funded internationally
■ Funded domestically